Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EPS (Basic) (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of EPS (Basic) data on record, last reported at -$0.02 in Q3 2025.

  • For Q3 2025, EPS (Basic) changed 0.0% year-over-year to -$0.02; the TTM value through Sep 2025 reached -$0.07, down 16.67%, while the annual FY2024 figure was -$0.07, 16.67% down from the prior year.
  • EPS (Basic) reached -$0.02 in Q3 2025 per NWBO's latest filing, roughly flat from -$0.02 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.22 in Q2 2022 and bottomed at -$15.51 in Q2 2021.
  • Average EPS (Basic) over 5 years is -$1.07, with a median of -$0.02 recorded in 2025.
  • The widest YoY moves for EPS (Basic): up 141.03% in 2021, down 19291.18% in 2021.
  • A 5-year view of EPS (Basic) shows it stood at $0.16 in 2021, then plummeted by 112.5% to -$0.02 in 2022, then soared by 50.0% to -$0.01 in 2023, then crashed by 100.0% to -$0.02 in 2024, then grew by 0.0% to -$0.02 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.02 in Q3 2025, -$0.02 in Q2 2025, and -$0.01 in Q1 2025.